Citius Pharmaceuticals Management

Management criteria checks 2/4

Citius Pharmaceuticals' CEO is Leonard Mazur, appointed in Mar 2016, has a tenure of 8.67 years. total yearly compensation is $1.98M, comprised of 24% salary and 76% bonuses, including company stock and options. directly owns 5.67% of the company’s shares, worth €3.66M. The average tenure of the management team and the board of directors is 3.8 years and 8.5 years respectively.

Key information

Leonard Mazur

Chief executive officer

US$2.0m

Total compensation

CEO salary percentage	24.0%
CEO tenure	8.7yrs
CEO ownership	5.7%
Management average tenure	3.8yrs
Board average tenure	8.5yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Leonard Mazur's remuneration changed compared to Citius Pharmaceuticals's earnings?
Date	Total Compensation	Salary	Company Earnings
Jun 30 2024	n/a	n/a	-US$40m
Mar 31 2024	n/a	n/a	-US$37m
Dec 31 2023	n/a	n/a	-US$39m
Sep 30 2023	US$2m	US$475k	-US$34m
Jun 30 2023	n/a	n/a	-US$31m
Mar 31 2023	n/a	n/a	-US$31m
Dec 31 2022	n/a	n/a	-US$28m
Sep 30 2022	US$1m	US$400k	-US$34m
Jun 30 2022	n/a	n/a	-US$31m
Mar 31 2022	n/a	n/a	-US$29m
Dec 31 2021	n/a	n/a	-US$26m
Sep 30 2021	US$788k	US$348k	-US$25m
Jun 30 2021	n/a	n/a	-US$24m
Mar 31 2021	n/a	n/a	-US$21m
Dec 31 2020	n/a	n/a	-US$21m
Sep 30 2020	US$550k	US$250k	-US$18m
Jun 30 2020	n/a	n/a	-US$17m
Mar 31 2020	n/a	n/a	-US$17m
Dec 31 2019	n/a	n/a	-US$16m
Sep 30 2019	US$473k	US$250k	-US$16m
Jun 30 2019	n/a	n/a	-US$15m
Mar 31 2019	n/a	n/a	-US$12m
Dec 31 2018	n/a	n/a	-US$13m
Sep 30 2018	US$398k	US$250k	-US$13m

Compensation vs Market: Leonard's total compensation ($USD1.98M) is above average for companies of similar size in the German market ($USD486.57K).

Compensation vs Earnings: Leonard's compensation has increased whilst the company is unprofitable.

CEO

Leonard Mazur (79 yo)

8.7yrs

Tenure

US$1,981,113

Compensation

Mr. Leonard L. Mazur is Chairman, Chief Executive Officer & President of Citius Oncology, Inc. from August 12, 2024. Mr. Mazur has been Chief Executive Officer of Citius Pharmaceuticals, Inc. since May 01,...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Leonard Mazur	Co-Founder	8.7yrs	US$1.98m	5.67% € 3.7m
Myron Holubiak	Co-Founder & Executive Vice Chairman	9.1yrs	US$1.59m	1.1% € 710.4k
Myron Czuczman	Executive VP & Chief Medical Officer	4.3yrs	US$1.17m	0% € 0
Jaime Bartushak	Chief Business Officer	7yrs	US$809.00k	0.033% € 21.5k
Gary Talarico	Executive Vice President of Operations	8.7yrs	no data	no data
Ilanit Allen	Vice President of Investor Relations & Corporate Communications	no data	no data	no data
Alan Lader	Senior VP and Head of Clinical Operations & Quality Assurance	2.8yrs	no data	no data
Dhananjay Wadekar	Senior Vice President of Business Strategy	3.8yrs	no data	no data
Kelly Creighton	Executive Vice President of Chemistry	3yrs	no data	no data
Nikolas Burlew	Executive Vice President of Quality Assurance	1.8yrs	no data	no data
Catherine Kessler	Executive Vice President of Regulatory Affairs	1.2yrs	no data	no data

3.8yrs

Average Tenure

69.5yo

Average Age

Experienced Management: 47N's management team is considered experienced (3.8 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Leonard Mazur	Co-Founder	10.2yrs	US$1.98m	5.67% € 3.7m
Myron Holubiak	Co-Founder & Executive Vice Chairman	9.1yrs	US$1.59m	1.1% € 710.4k
Dennis McGrath	Independent Director	1.8yrs	US$150.13k	0% € 0
Michael Matthay	ARDS Scientific Advisory Board Member	no data	no data	no data
Suren Dutia	Independent Director	9.1yrs	US$196.97k	0% € 0
Carol Webb	Independent Director	8.7yrs	US$190.97k	0.0066% € 4.2k
Eugene Holuka	Independent Director	8.4yrs	US$190.97k	0.0013% € 844.2
Issam Raad	Chairman of Scientific Advisory Board	no data	no data	no data
Mark Rupp	Member of Scientific Advisory Board	no data	no data	no data
Leonard Mermel	Member of Scientific Advisory Board	6.3yrs	no data	no data
John Laffey	ARDS Scientific Advisory Board Member	3.4yrs	no data	no data
Lorraine Ware	ARDS Scientific Advisory Board Member	no data	no data	no data

8.5yrs

Average Tenure

77yo

Average Age

Experienced Board: 47N's board of directors are considered experienced (8.5 years average tenure).

Citius Pharmaceuticals Management

Management criteria checks 2/4

Key information

Recent management updates

Citius Pharmaceuticals, Inc., Annual General Meeting, Mar 12, 2024

Citius Pharmaceuticals, Inc. Announces Changes to its Audit Committee

Citius Pharmaceuticals, Inc. Appoints Dennis M. McGrath to Board of Directors

Citius Pharmaceuticals, Inc., Annual General Meeting, Feb 07, 2023

Insufficient new directors

Insufficient new directors

Recent updates

Citius Pharmaceuticals, Inc. Provides Non-Compliance Update

New minor risk - Market cap size

Citius Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $50 million.

Citius Pharmaceuticals, Inc. Receives FDA Approval for LYMPHIR Immunotherapy for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma

Forecast breakeven date pushed back to 2026

Citius Pharmaceuticals, Inc. Achieves Primary and Secondary Endpoints in Phase 3 Trial of Mino-Lok Antibiotic Lock Solution

Citius Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $15.000002 million.

Citius Pharmaceuticals, Inc. Announces Addition of City of Hope to UMN's Phase 1 Trial of LYMPHIR in Combination with CAR-T for the Treatment of B-Cell Lymphoma

New major risk - Share price stability

The Nasdaq Stock Market LLC Grants Citius Pharmaceuticals' Request for an Extension through September 9, 2024 to Evidence Compliance with the Bid Price Rule Pursuant to Nasdaq Listing Rule 5550(a)(2)

Forecast breakeven date pushed back to 2026

Citius Pharmaceuticals, Inc. Announces the Resubmission of the Biologics License Application to the U.S. Food and Drug Administration for Lymphir

New minor risk - Market cap size

Citius Pharmaceuticals, Inc., Annual General Meeting, Mar 12, 2024

Citius Pharmaceuticals, Inc. Completes Enrollment in Pivotal Phase 3 Trial of its Mino-Lok Therapeutic to Salvage Catheters

New minor risk - Profitability

Citius Pharmaceuticals, Inc. Announces Publication in Frontiers of Immunology of Positive Results from Solid Tumor Study of LYMPHIR™ in Combination with Checkpoint Inhibitor

Citius Pharmaceuticals, Inc. Announces Changes to its Audit Committee

Citius Pharmaceuticals Receives Non-Compliance Notice from Nasdaq Stock Market

Citius Pharmaceuticals Receives Non-Compliance Notice from Nasdaq Stock Market

Citius Pharmaceuticals, Inc. Receives Regulatory Guidance from the U.S. Food and Drug Administration Regarding the Planned Resubmission of the BLA for LYMPHIR

Citius Pharmaceuticals, Inc. Reaches 92 Event Milestone in Mino-Lok Phase 3 Trial

Citius Pharmaceuticals, Inc. Receives a Complete Response Letter from the U.S. Food and Drug Administration (FDA) for LYMPHIR™ (Denileukin Diftitox) for the Treatment of Patients with Relapsed or Refractory Cutaneous T-Cell Lymphoma

Citius Pharmaceuticals, Inc. Announces Positive Results from the Phase 2b Study of Halo-Lido (CITI-002) for the Treatment of Hemorrhoids

Forecast breakeven date pushed back to 2025

Forecast breakeven date pushed back to 2025

Citius Pharmaceuticals, Inc. Appoints Dennis M. McGrath to Board of Directors

Citius Pharmaceuticals, Inc., Annual General Meeting, Feb 07, 2023

Citius Pharmaceuticals, Inc. Announces U.S. Food and Drug Administration Acceptance of Biologics License Application of Denileukin Diftitox for Treatment of Patients with Persistent or Recurrent Cutaneous T-Cell Lymphoma

Insufficient new directors

Citius Pharmaceuticals, Inc. Submits Biologics License Application to the U.S. Food and Drug Administration for Denileukin Diftitox for the Treatment of Patients with Persistent or Recurrent Cutaneous T-Cell Lymphoma

Citius Pharmaceuticals, Inc. Holds Pre-BLA Meeting with the FDA for I/ONTAK for the Treatment of Cutaneous T-Cell Lymphoma

Insufficient new directors

Citius Pharmaceuticals, Inc. Enrolls First Patient in Phase 2B Study of Halo-Lido for the Prescription Treatment of Hemorrhoids

Citius Pharmaceuticals, Inc. Announces Executive Changes

Forecast breakeven date pushed back to 2024

Citius Pharmaceuticals Reports Topline Data from the Pivotal Phase 3 Study of Cancer Immunotherapy I/Ontak (E7777)

Citius Pharmaceuticals Announces FDA Acceptance of IND Application for its Phase 2b Study of Halo-Lido for the Prescription Treatment of Hemorrhoids

Forecast breakeven date moved forward to 2023

Citius Pharmaceuticals, Inc. Completes Enrollment in the Pivotal Phase 3 Study of its Cancer Immunotherapy I/ONTAK for the Treatment of Cutaneous T-Cell Lymphoma

Citius Pharmaceuticals Acquires Dr. Reddy's Laboratories' License for Late-Phase 3 Oncology Immunotherapy (E7777) for the Treatment of Cutaneous T-Cell Lymphoma and other Cancer Indications

Citius Pharmaceuticals, Inc. (NasdaqCM:CTXR) agreed to acquire Rights and Certain Related Assets of Dr. Reddy's Laboratories Limited (BSE:500124) for approximately $150 million.

Citius Pharmaceuticals, Inc. Announces Positive Recommendation by Independent Data Monitoring Committee to Continue the Mino-Lok® Phase 3 Trial as Planned

Citius Pharmaceuticals Achieves Next Interim Analysis Milestone in its Mino-Lok® Phase 3 Trial

Citius Pharmaceuticals, Inc. Reports Strong Clinical Community Engagement During Mino-Lok Phase 3 Trial-Related Webinar

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age